Where Cholesterol Surrogates Stand After ACC '16
Failure of another CETP inhibitor – Lilly’s evacetrapib – despite robust LDL-lowering raises more doubt about surrogates, yet doesn’t put too much of a damper on PCSK9 inhibitors at the annual American College of Cardiology meeting. Statins get another boost just ahead of entry of Crestor generics.
You may also be interested in...
Blood pressure and C-reactive protein were modestly increased in the ACCELERATE trial of Lilly’s CETP inhibitor evacetrapib, but what exactly torpedoed the trial is still a mystery.
FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?
Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.